Atlas Trials

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Clinical trial NCT03010228 · COMPLETED

Trial details

NCT number
NCT03010228
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Lyme Borreliosis, Nervous System
Start date
2017-01-31
Primary completion
2017-09-28
Enrollment
179

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.